The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The evolving role of venetoclax in CLL
Alexey V. Danilov, MD, PhD , City of Hope, Duarte, CA, discusses the role of venetoclax in chronic lymphocytic leukemia (CLL), highlighting the advantages of this drug and commenting on how its role may evolve in the future. Currently, venetoclax is used in combination with CD20-directed antibodies in the frontline and relapsed setting, and as a single agent in patients carrying deletion 17p (del17p). However, multiple ongoing trials are evaluating the use of venetoclax in combination with various BTK inhibitors and are showing promising results. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
